Biomarker profiling to understand metabolic syndrome in pregnant women with HIV on DTG-based ART
Official title: Integrated proteomic and metabolomic biomarker profiling for understanding metabolic syndrome in pregnant women living with HIV on Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir (TLD)
Funded at Johns Hopkins University · NIH-11593951 · Data updated 2026-11-12
This project looks at why some pregnant women living with HIV on a common DTG-based therapy gain weight or develop metabolic problems, by studying their proteins and metabolites across four sites in the US and Nigeria.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 5, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $38,880 |
| NIH project number | 3DP1HD115433-03S2 |
| Project ID | NIH-11593951 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants are pregnant or recently postpartum women living with HIV who are on DTG-based ART.
✕Less likely to help
Participants not on DTG-based ART or not pregnant/postpartum may have limited direct benefit.
What this research studies
Researchers will follow pregnant and postpartum women living with HIV who are on DTG-based ART at four sites in two countries to collect clinical data and biological samples. They will analyze proteins and metabolites to identify biomarkers linked to metabolic syndrome and weight gain during pregnancy. The study combines clinical information with advanced omics profiling to better understand who is at risk and why these metabolic changes occur. The results could guide safer ART choices and early interventions to reduce pregnancy complications.
Why it matters
Potential benefit: If successful, the findings could help tailor HIV treatment during pregnancy to minimize weight gain and metabolic problems, improving maternal and newborn health.
How similar studies have gone: Prior studies have linked DTG-based ART with metabolic changes, but this project adds integrated proteomic and metabolomic profiling to uncover underlying mechanisms.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Eke, Ahizechukwu C. — Johns Hopkins University
- Study coordinator: Eke, Ahizechukwu C.
Related research
Other NIH-funded projects on the same topics.
-
Integrated biomarker study of metabolic syndrome in pregnant women with HIV on DTG-based ART
Researchers will look for biological signs in pregnant women with HIV on a DTG-based regimen to understand why weight gain and metabolic problems happen and how these affect pregnancy.
-
Biomarker profiling to understand metabolic syndrome in pregnant women with HIV on DTG-based therapy
This project looks at markers in pregnant women living with HIV who are on a DTG-containing regimen to understand why some develop metabolic problems during pregnancy.
-
Biomarker profiling to understand metabolic syndrome in pregnant women with HIV on a DTG-based regimen
Researchers will study blood and metabolite markers in pregnant women with HIV on a DTG-based regimen to understand why weight gain and metabolic problems may occur during pregnancy.
-
Understanding metabolic syndrome in pregnant women with HIV on specific treatments
This study is looking at how a specific HIV treatment called Dolutegravir affects weight gain and overall health in pregnant women with HIV, to help understand any health challenges they might face during pregnancy.
-
Choline for fetal brain protection in pregnant women who drink heavily
Giving choline to pregnant women who drink heavily may help protect the baby’s brain and improve early development.
-
Mentor Moms+: a community-led plan to cut alcohol use and HIV risk during pregnancy in South Africa
A community-based program adapts a trusted peer-led model to help pregnant and lactating people reduce alcohol use and HIV risk in South Africa.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.